FcRn Inhibitor
Jul 15, 2024
FcRn Inhibitors Being The Fastest Growing Class, Plans To Get Explored In 20+ Indications
Vyvgart enjoying strong commercial uptake whereas RYSTIGGO is preferred for MuSK+ Myasthenia gravis. What do the physicians believe? The neonatal Fc receptor (FcRn) inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma, along with a few early-stage players ...
Read More...
May 06, 2024
FcRn Inhibitors for Autoimmune Disorders: A Promising Therapeutic Approach
Autoimmune disorders, a group of conditions where the immune system mistakenly attacks healthy cells, affect millions worldwide, often leading to debilitating symptoms and reduced quality of life. Traditional treatments for autoimmune disorders have primarily focused on suppressing the immune system, which can leav...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
